Table 3 Antimicrobial resistance of multidrug-resistant Escherichia coli
Participant | Country of study | Resistance profile | Â | Antimicrobial Resistance Testing | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Amikacin | Ampicillin- Sulbactam | Aztreonam | Cefepime | Cefoxitin | Ceftazidime | Ceftriaxone | Cefuroxime | Ciprofloxacin | Ertapenem | Gentamicin | Imipenem | Levofloxacin | Meropenem | Moxifloxacin | Nitrofurantoin | Piperacillin- Tazobactam | Tobramycin | Trimethoprim- Sulfamethoxazole |
6 | US | MDR | S | R | R | S | R | R | R | R | R | S | R | S | R | S | R | S | R | I | R |
6 | US | MDR | S | R | R | S | R | R | R | R | R | S | R | S | R | S | R | S | R | I | R |
9 | US | ESBL | S | R | R | R | I | R | R | R | R | S | S | S | R | S | R | S | S | S | R |
% susceptible by unique isolate per unique participant | 100 | 0 | 0 | 50 | 0 | 0 | 0 | 0 | 0 | 100 | 50 | 100 | 0 | 100 | 0 | 100 | 50 | 50 | 0 | ||
1 | Afghan | MDR | S | R | R | S | R | R | R | R | S | S | S | S | S | S | S | S | I | S | R |
1 | Afghan | MDR | S | R | R | S | R | R | R | R | S | S | S | S | S | S | S | S | I | S | R |
2 | Afghan | ESBL | S | R | R | R | I | R | R | R | R | S | R | S | R | S | R | S | S | R | R |
3 | Afghan | ESBL | S | R | R | R | S | R | R | R | S | S | S | S | S | S | S | S | S | S | R |
3 | Afghan | ESBL | S | R | R | R | S | R | R | R | S | S | S | S | S | S | S | S | I | S | R |
4 | Afghan | ESBL | S | R | R | R | I | R | R | R | S | S | S | S | S | S | S | S | S | S | S |
5 (PFT 5) | Afghan | ESBL | S | R | R | R | S | R | R | R | S | S | S | S | S | S | S | S | S | S | R |
5 (PFT 8) | Afghan | ESBL | S | R | R | R | S | R | R | R | R | S | S | S | R | S | R | S | S | R | R |
7 | Afghan | ESBL | S | R | R | R | S | R | R | R | R | S | S | S | R | S | R | I | S | S | R |
8 | Afghan | ESBL | S | R | R | R | S | R | R | R | R | S | S | S | R | S | R | S | S | R | R |
10 | Afghan | ESBL | S | R | R | R | S | R | R | R | S | S | S | S | S | S | S | I | S | S | R |
11 | Afghan | ESBL | S | R | R | R | S | R | R | R | R | S | S | S | R | S | R | S | S | S | R |
12 | Afghan | ESBL | S | R | R | R | S | R | R | R | S | S | S | S | S | S | I | S | S | S | R |
12 | Afghan | ESBL | S | R | R | R | S | R | R | R | S | S | S | S | S | S | I | S | S | S | R |
13 | Afghan | ESBL | S | R | R | R | S | R | R | R | R | S | S | S | R | S | R | S | S | R | R |
% susceptible by unique isolate per unique participant | 100 | 0 | 0 | 8 | 75 | 0 | 0 | 0 | 42 | 100 | 92 | 100 | 50 | 100 | 42 | 83 | 92 | 75 | 8 | ||